RKRani Khatib

Rani Khatib

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Rani Khatib has a total of 156 co-authors. Here are the top co-authors by number of shared publications:

  • Abigail Barrowcliff

    Cardiology Department, Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom

    3 shared publications
  • Alistair Hall

    Cardio-Respiratory Department, Leeds Teaching Hospitals NHS Trust, Leeds, UK

    3 shared publications
  • Ercole Vellone

    Department of Biomedicine and Prevention, University of Rome Tor Vergata, 00133 Rome, Italy

    3 shared publications
  • Geraldine A Lee

    Florence Nightingale Faculty of Nursing, Midwifery and Palliative Care , James Clerk Maxwell Building, 57 Waterloo Road, London SE1 8WA , UK

    3 shared publications
  • Geraldine Lee

    Catherine McAuley School of Nursing & Midwifery, Brookfield Health Sciences Complex, University College Cork, Cork, Ireland

    3 shared publications
  • Alistair S Hall

    Cardiology Department, Leeds Teaching Hospitals NHS Trust, Leeds, UK

    2 shared publications

Latest Publications

  • Perspectives on caregiver-reported outcomes in cardiovascular diseases today and in future healthcare services: a statement of Association of Cardiovascular Nursing & Allied Professions (ACNAP), Association for Acute CardioVascular Care (ACVC), the Heart Failure Association (HFA), ESC Council on Stroke, and Global Heart Hub, the International Alliance of Heart Patient Organisations

    by Irene Lie, Britt Borregaard, Suzanne Fredericks, Annie Costelloe, Angela Durante, Johannes Grand, Loreena Hill, Rani Khatib, Martha Kyriakou, Ekaterini Lambrinou, et al.

    A rapidly ageing population implies an increasing demand for informal caregivers. Caregiver-reported outcomes (CROs) can provide valuable insights into caregivers’ experiences of their own health, the burden of tasks, and the need for support. This scientific statement provides a comprehensive overview of CROs in populations with cardiovascular diseases (CROsCVD). The existing CROs measure impact of caregiving; caregiver skills and preparedness; caregiver emotional and psychological impact; and caregiver support. The integration of CROs into clinical practice, alongside the development of more specific and culturally adaptive tools, will enhance the recognition of caregivers as key stakeholders in CVD management.

  • Open Access

    Cardiovascular risk estimation and statin adherence An historical cohort study

    by Samuel Finnikin, Brian Willis, Tim Evans, Brian Finney, Kwan Nok Chris Hui, Rani Khatib, Tom Marshall

    Background Adherence to statins for the primary prevention of cardiovascular disease (CVD) is low. There is evidence that some facets of the initiation consultation, or the initiating clinician, are associated with adherence. CVD risk estimation is fundamental to statin initiation and shared decision making (SDM), because the benefits of statins are proportional to CVD risk. Absence of a recorded CVD risk score before statin initiation therefore indicates SDM is unlikely. This study investigates whether, in primary prevention, SDM, using CVD risk score as a proxy measure, is associated with adherence to statins and CVD outcomes. Method A cohort of statin naïve patients aged 40-84 years initiated on statins for primary prevention between 2017 and 2020 was identified and categorised by the presence or absence of a CVD risk score at statin initiation. Statin adherence and persistence was determined from subsequent statin prescriptions. Multivariable modelling, accounting for potential confounders determined the association between a recorded CVD risk score and statin adherence and persistence. A secondary analysis investigated the relationship with subsequent CVD outcomes and death. Results 255,730 patients were included with a mean follow up of 4.6 years. 67.7% had a CVD risk score coded. The presence of a CVD risk score increased odds of adherence at the end of year one by 7% and reduced the chances of discontinuation by 8%. The composite outcome of CVD and all-cause mortality was decreased by 21% when a CVD risk score was present. Conclusion When a statin is initiated in the presence of a CVD risk score there is a small, but significant improvement in both adherence and persistence which could indicate that the quality of initiation consultations, and a focus on SDM, improves the utility of statins. Additionally, CVD risk scoring is associated with a large decrease in CVD/death which cannot fully be explained by improvements in statin adherence and persistence; an important finding necessitating further investigation. What is new? We present a comprehensive assessment of the adherence to and persistence with statins for the primary prevention of CVD which, for the first time, is linked to the presence or absence of CVD risk scoring. CVD risk scoring is associated with improvements and both adherence and persistence as well as significant reductions in CVD and all-cause mortality. What are the clinical implications? There should be renewed focus on the content of statin initiation consultations ensuring that CVD risk is communicated using a shared decision-making approach. Further consideration should be given to the important discrepancy in CVD and death seen when CVD risk scoring is, and is not, used in practice.

  • Open Access

    Supporting appropriate use of extended dual antiplatelet therapy post-myocardial infarction based on an innovative 12-month ticagrelor virtual service

    by \R\Nrani Khatib, Abigail Barrowcliff, Franki Wilson, Sidra Awan, Mutiba Khan, Stephen Wheatcroft, Alistair S. Hall

    Purpose: Extended dual antiplatelet therapy (DAPT) with ticagrelor and aspirin is recommended in selected cases after myocardial infarction (MI) but not widely deployed in practice. This study assessed an innovative, cardiology pharmacist-led virtual service for determining eligibility for extended DAPT among patients completing 12 months of initial DAPT in primary care following MI.Methods: Within this model, potentially eligible individuals are reviewed virtually by a cardiology pharmacist for suitability for extended DAPT with reduced-dose ticagrelor [60 mg twice daily (BD)] for up to 3 years. Eligibility is guided by the PEGASUS-TIMI 54 trial criteria (aged ≥50 years and having ≥1 high-risk feature for further ischaemic events). This is balanced against potential ineligibility driven primarily by bleeding risk, assessed using PRECISE-DAPT score. The final recommendation is sent to primary care to action. The present work is a retrospective evaluation of patients referred to the service between July 2018 and December 2021.Results: A total of 200 patients were included [n = 131 (65.5%) male; mean age: 69.4 ± 9.5 years]. Of these, 79 (39.5%) were recommended for extended DAPT based on the balance of risks for further ischaemic events vs. bleeding. Sixty-three patients on high-dose DAPT (ticagrelor 90 mg BD)—which is inappropriate beyond 12 months—were reassigned to reduced-dose DAPT or aspirin monotherapy.Conclusions: This virtual clinic played a key role in medicines optimisation, enabling appropriate patients to benefit from extended DAPT while offsetting bleeding risk. The model could be adapted locally for use elsewhere.


  • Open Access

    Healthcare professionals’ perspectives on the use of PCSK9 inhibitors in cardiovascular disease: an in-depth qualitative study

    by Geraldine A Lee, Angela Durante, Edward E Baker, Ercole Vellone, Gabriele Caggianelli, Federica Dellafiore, Mutiba Khan, Rani Khatib

    Aims: Injectable medicines such as PCSK9 inhibitors are increasingly used to manage risk factors for cardiovascular events with little information around the perceptions of healthcare professionals (HCPs) on the administrative and clinical practicalities. The aim was to identify the facilitators and barriers on the use of injectable therapies with cardiovascular benefits through interviews with HCPs. Methods and results: Qualitative interviews were conducted in the UK (London and Leeds) and Italy (Rome and Milan) in 2021. Coding was undertaken using NVivo and thematic analysis performed. A total of 38 HCPs were interviewed, 19 in each country composing of physicians (n = 18), pharmacists (n = 10), nurses (n = 9), and pharmacy technician (n = 1). Four themes emerged: (i) clinicians’ previous experiences with injectable therapies, (ii) challenges with patients’ behaviours and beliefs, (iii) clinicians’ knowledge of injectable therapies and therapeutic inertia, and (iv) organizational and governance issues. The behaviour and beliefs from HCPs focused on facilitating behaviour change as well as the poor interdisciplinary working and collaboration. Therapeutic inertia was raised where physicians either lacked awareness of injectable therapies or were unwilling to prescribe them. The importance of facilitating patient education on injection techniques was highlighted, while organizational and governance issues identified the lack of guidance to inform practice. Clear pathways are required to identify those who were eligible for injectable therapies as well as on how injectables should be prescribed. Conclusion: If medicine optimization is to be achieved, there need to be structured processes in place to identify eligible patients and the development of educational material.


  • Open Access

    Developing a post-myocardial infarction medicines optimisation clinic: core competencies for upskilling pharmacists and initial patient feedback

    by Ruth Price, Franki Wilson, Alistair Hall, Gina McGawley, Una Laverty, Chris Pepper, Rani Khatib

    Background Medicines optimisation and adherence support are essential to secondary prevention after myocardial infarction (MI). Following successful implementation of a consultant pharmacist-led post-MI medicines optimisation clinic, the service was expanded by training advanced clinical pharmacists to manage clinics (with appropriate multidisciplinary team support). Methods Key steps in the development process were: definition of a key competency framework based on relevant qualifications and experience, knowledge, skills and clinic management practicalities; creation and enaction of trainee-specific development plans to address gaps (including independent learning, teaching from multidisciplinary colleagues and shadowing in clinics); establishment of relevant protocols and proformas to ensure consistent standards (eg, a patient self-reporting tool for identifying adherence barriers, consultation proforma, directory of clinical parameters and pathway for onward referral when needed); phased clinic roll-out, initially under supervision; and gathering of feedback from patients and colleagues. Clinic letters from 50 attending patients were reviewed to quantify resulting interventions; the first 50 anonymously completed patient feedback questionnaires were also analysed. Results Expansion of the service initially doubled capacity. A review of clinic letters from attending patients demonstrated that various interventions were recommended, including further investigations, medication changes, lifestyle adjustments and onward referrals. Most respondents to the patient feedback questionnaire thought the clinic was patient friendly and welcoming (n=48/50; 96%); felt listened to (n=48/50; 96%); considered that adequate explanation was given (n=47/50; 94%); and felt clear plans were provided (n=45/49; 92%). Most agreed that it was valuable (n=44/50; 88%), and the mean rating was 4.48 (on a scale of 1 (very poor) to 5 (excellent)). Conclusions A person-centred post-MI medicines optimisation service was successfully delivered by appropriately trained advanced cardiology pharmacists. A structured competency framework and training programme were required, but once completed, the clinic was highly valued by patients. A similar model could be rolled out elsewhere with adaption to local requirements.


  • Open Access

    Innovative, centralised, multidisciplinary medicines optimisation clinic for PCSK9 inhibitors

    by Rani Khatib, Mutiba Khan, Abigail Barrowcliff, Eunice Ikongo, Claire Burton, Michael Mansfield, Alistair Hall

    Background: Proprotein convertase subtilisin/kexin type 9 inhibitors (PCSK9is) are an important but underutilised option to help optimise lipid management. We developed a new service to improve patient access to these medicines in line with National Institute for Health and Care Excellence recommendations. This paper describes the model and provides lipid-lowering results and feedback from the first 100 referred patients. Methods: The service is based on a centralised multidisciplinary clinic that is the sole prescriber of PCSK9i therapy in the area. Referred patients are assessed for eligibility and given tailored, person-centred support, education and monitoring to promote treatment adherence and lipids optimisation. The clinic also supports referred patients that do not meet PCSK9i eligibility criteria. Results: Among the first 100 patients referred (n=62 male; mean age: 62.9±10.5 years), 48 were initiated on PCSK9i therapy. Mean total cholesterol decreased from 7.7±1.6 mmol/L at baseline to 4.5±1.4 mmol/L at 3 months (41% reduction), while mean low-density lipoprotein-cholesterol (LDL-C) fell from 5.0±1.6 mmol/L to 2.1±1.3 mmol/L (58% reduction; p<0.0001 for the decrease in mean LDL-C from baseline). Patient feedback on the clinic was positive and overall satisfaction was high. Conclusions: This innovative, person-centred, multidisciplinary service successfully initiated PCSK9i therapy for eligible patients and drove long-term monitoring, adherence and cholesterol lowering. It also provided medicines optimisation and adherence assistance to PCSK9i-ineligible patients. The model could be used in other areas to support better uptake and optimisation of PCSK9i therapy.


  • Hospital–pharma clinic partnerships: a bridge too far?

    by Rani Khatib

    Meeting patient needs Previously, individuals with CV disease and type 2 diabetes in our area were treated by two separate specialty teams. However, it is now well-established that there is significant interplay between CV and metabolic disease, as well as renal disorders.2,3 Thus, we have come to believe th ...

  • Open Access

    Perceptions of injectable therapies with cardiovascular benefit: an ACNAP survey of healthcare professionals to explore facilitators and barriers

    by Rani Khatib, Neil Angus, Tina B Hansen, Ekaterini Lambrinou, Ercole Vellone, Mutiba Khan, Geraldine A Lee

    Aims: Injectable medicines are increasingly used to manage risk factors for cardiovascular (CV) events, such as dyslipidaemia and diabetes. These include proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists. Little is known about perceptions of injectable therapies among CV healthcare professionals (HCPs). This study explores their views to identify relevant facilitators and barriers to the use of injectables with CV benefit. Methods and results: A 22-question survey was distributed internationally via online channels. In total, 192 anonymous responses were received (43.7% physicians, 32.6% nurses, 16.8% pharmacists, 6.8% others). Among respondents with experience of these medicines, 69.1% had used an injectable PCSK9 inhibitor and 67.0% had used an injectable GLP-1 receptor agonist. Commonly raised issues were resource problems (36.5%), lack of knowledge among colleagues (32.3%), paperwork (32.3%), and lack of patient knowledge (28.1%). Key barriers respondents felt made patients decline these treatments were fear of injection (56.6%), lack of awareness or education (26.4%), and administration issues (15.1%); potential reasons for discontinuation included side effects (46.4%), perceived lack of benefit (28.6%), and local reactions (21.4%). The main topics around injectables requiring further support included managing non-adherent patients (16.2%), troubleshooting with patients (16.2%), and educating colleagues about injectables (12.2%). Preferred educational methods to support HCPs were face-to-face training (43.5%) and online learning (26.1%); favoured formats were based on role playing and case studies. Conclusion: Healthcare professionals highlighted various potential barriers to initiation, continuation, and adherence with injectable therapies in CV medicine. Although some require healthcare system changes, many could be addressed through simple measures based primarily on enhanced training and support for patients and HCPs.